

Hua-Xin Liao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6162241/publications.pdf>

Version: 2024-02-01

82
papers

7,367
citations

70961

41
h-index

60497

81
g-index

82
all docs

82
docs citations

82
times ranked

6944
citing authors

#	ARTICLE	IF	CITATIONS
1	Allelic imbalance of HLA-B expression in human lung cells infected with coronavirus and other respiratory viruses. <i>European Journal of Human Genetics</i> , 2022, , .	1.4	10
2	Genome-wide identification of key regulatory lncRNAs in esophageal cancer metastasis. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 88.	7.1	15
3	Structural basis of tetanus toxin neutralization by native human monoclonal antibodies. <i>Cell Reports</i> , 2021, 35, 109070.	2.9	10
4	Exploiting Pre-Existing CD4+ T Cell Help from Bacille Calmette-Guérin Vaccination to Improve Antiviral Antibody Responses. <i>Journal of Immunology</i> , 2020, 205, 425-437.	0.4	3
5	Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1375-1387.	2.0	75
6	Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth. <i>Nature Immunology</i> , 2020, 21, 199-209.	7.0	68
7	<p>A Multi-Element Expression Score Is A Prognostic Factor In Glioblastoma Multiforme</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 8977-8989.	0.9	6
8	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2019, 15, e1008026.	2.1	56
9	Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector. <i>Viruses</i> , 2019, 11, 159.	1.5	13
10	Selection of immunoglobulin elbow region mutations impacts interdomain conformational flexibility in HIV-1 broadly neutralizing antibodies. <i>Nature Communications</i> , 2019, 10, 654.	5.8	34
11	HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. <i>Journal of Virology</i> , 2018, 92, .	1.5	46
12	Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes. <i>Journal of Virology</i> , 2018, 92, .	1.5	30
13	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. <i>Journal of Virology</i> , 2018, 92, .	1.5	10
14	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. <i>Journal of Virology</i> , 2018, 92, .	1.5	45
15	Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. <i>Journal of Virology</i> , 2018, 92, .	1.5	24
16	Intra-seasonal antibody repertoire analysis of a subject immunized with an MF59®-adjuvanted pandemic 2009 H1N1 vaccine. <i>Vaccine</i> , 2018, 36, 5325-5332.	1.7	4
17	Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. <i>Journal of Experimental Medicine</i> , 2018, 215, 1571-1588.	4.2	366
18	Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. <i>Immunological Reviews</i> , 2017, 275, 145-160.	2.8	160

#	ARTICLE	IF	CITATIONS
19	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. <i>Science Immunology</i> , 2017, 2, .	5.6	119
20	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. <i>Cell Reports</i> , 2017, 18, 2175-2188.	2.9	69
21	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. <i>Nature Communications</i> , 2017, 8, 15711.	5.8	137
22	Staged induction of HIV-1 glycanâ€“dependent broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	212
23	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	81
24	HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 859-868.	0.5	18
25	Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120. <i>Journal of Virological Methods</i> , 2017, 249, 85-93.	1.0	2
26	Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. <i>Journal of Virology</i> , 2017, 91, .	1.5	19
27	Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies. <i>Journal of Virology</i> , 2017, 91, .	1.5	29
28	Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. <i>PLoS ONE</i> , 2017, 12, e0176428.	1.1	12
29	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. <i>Nature Communications</i> , 2017, 8, 1732.	5.8	76
30	Computational analysis of antibody dynamics identifies recent HIV-1 infection. <i>JCI Insight</i> , 2017, 2, .	2.3	11
31	Envelope-specific B-cell populations in African green monkeys chronically infected with simian immunodeficiency virus. <i>Nature Communications</i> , 2016, 7, 12131.	5.8	14
32	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. <i>Molecular Therapy</i> , 2016, 24, 2021-2032.	3.7	41
33	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. <i>EBioMedicine</i> , 2016, 14, 97-111.	2.7	47
34	HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence. <i>Immunogenetics</i> , 2016, 68, 145-155.	1.2	18
35	A Therapeutic Antibody for Cancer, Derived from Single Human B Cells. <i>Cell Reports</i> , 2016, 15, 1505-1513.	2.9	43
36	Novel Monoclonal Antibodies for Studies of Human and Rhesus Macaque Secretory Component and Human J-Chain. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2016, 35, 217-226.	0.8	9

#	ARTICLE	IF	CITATIONS
37	HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. <i>Journal of Immunology</i> , 2016, 197, 4663-4673.	0.4	6
38	Initiation of immune tolerance—controlled HIV gp41 neutralizing B cell lineages. <i>Science Translational Medicine</i> , 2016, 8, 336ra62.	5.8	86
39	Immune perturbations in HIV-1—infected individuals who make broadly neutralizing antibodies. <i>Science Immunology</i> , 2016, 1, aag0851.	5.6	120
40	Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. <i>Nature Medicine</i> , 2016, 22, 1465-1469.	15.2	104
41	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. <i>EBioMedicine</i> , 2016, 12, 196-207.	2.7	34
42	Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds. <i>Journal of Virology</i> , 2016, 90, 5031-5046.	1.5	38
43	Interrogation of individual intratumoral B lymphocytes from lung cancer patients for molecular target discovery. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 171-180.	2.0	16
44	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. <i>Cell</i> , 2016, 165, 449-463.	13.5	305
45	Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. <i>Journal of Virology</i> , 2016, 90, 4951-4965.	1.5	23
46	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. <i>Cell Reports</i> , 2016, 14, 43-54.	2.9	45
47	Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa. <i>PLoS ONE</i> , 2016, 11, e0157391.	1.1	33
48	Immunogenic Stimulus for Germline Precursors of Antibodies that Engage the Influenza Hemagglutinin Receptor-Binding Site. <i>Cell Reports</i> , 2015, 13, 2842-2850.	2.9	67
49	Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. <i>Viruses</i> , 2015, 7, 5443-5475.	1.5	26
50	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. <i>PLoS Pathogens</i> , 2015, 11, e1005042.	2.1	145
51	Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. <i>Journal of Virology</i> , 2015, 89, 6462-6480.	1.5	40
52	Diversion of HIV-1 vaccine—induced immunity by gp41-microbiota cross-reactive antibodies. <i>Science</i> , 2015, 349, aab1253.	6.0	191
53	Viral Receptor-Binding Site Antibodies with Diverse Germline Origins. <i>Cell</i> , 2015, 161, 1026-1034.	13.5	151
54	Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1. <i>Journal of Virology</i> , 2015, 89, 9952-9961.	1.5	55

#	ARTICLE	IF	CITATIONS
55	Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140. <i>Journal of Virology</i> , 2015, 89, 8245-8257.	1.5	99
56	Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys. <i>Journal of Virology</i> , 2015, 89, 9485-9498.	1.5	8
57	Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee. <i>EBioMedicine</i> , 2015, 2, 713-722.	2.7	13
58	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. <i>Cell Host and Microbe</i> , 2015, 18, 354-362.	5.1	66
59	Potent Immune Responses in Rhesus Macaques Induced by Nonviral Delivery of a Self-amplifying RNA Vaccine Expressing HIV Type 1 Envelope With a Cationic Nanoemulsion. <i>Journal of Infectious Diseases</i> , 2015, 211, 947-955.	1.9	140
60	Progress in HIV-1 vaccine development. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 3-10.	1.5	62
61	Estimating the Probability of Polyreactive Antibodies 4E10 and 2F5 Disabling a gp41 Trimer after T Cell-HIV Adhesion. <i>PLoS Computational Biology</i> , 2014, 10, e1003431.	1.5	3
62	Reconstructing a B-Cell Clonal Lineage. II. Mutation, Selection, and Affinity Maturation. <i>Frontiers in Immunology</i> , 2014, 5, 170.	2.2	104
63	Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 10275-10280.	3.3	73
64	HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities. <i>Journal of Virology</i> , 2014, 88, 7715-7726.	1.5	169
65	Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved. <i>Immunity</i> , 2014, 41, 909-918.	6.6	65
66	Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAX [®] B/E in RV144 Vaccinees. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A36-A36.	0.5	1
67	Envelope Glycoprotein Binding to the Integrin $\alpha 4 \beta 7$ Is Not a General Property of Most HIV-1 Strains. <i>Journal of Virology</i> , 2014, 88, 10767-10777.	1.5	25
68	IGHV1-69 B Cell Chronic Lymphocytic Leukemia Antibodies Cross-React with HIV-1 and Hepatitis C Virus Antigens as Well as Intestinal Commensal Bacteria. <i>PLoS ONE</i> , 2014, 9, e90725.	1.1	37
69	Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide. <i>Journal of Virology</i> , 2014, 88, 9406-9417.	1.5	16
70	CD4-Mimetic Small Molecules Sensitize Human Immunodeficiency Virus to Vaccine-Elicited Antibodies. <i>Journal of Virology</i> , 2014, 88, 6542-6555.	1.5	55
71	HIV-1 Envelope gp41 Antibodies Can Originate from Terminal Ileum B Cells that Share Cross-Reactivity with Commensal Bacteria. <i>Cell Host and Microbe</i> , 2014, 16, 215-226.	5.1	105
72	Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. <i>Cell</i> , 2014, 158, 481-491.	13.5	266

#	ARTICLE	IF	CITATIONS
73	Antigenicity and Immunogenicity of Transmitted/Founder, Consensus, and Chronic Envelope Glycoproteins of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2013, 87, 4185-4201.	1.5	83
74	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. <i>Nature</i> , 2013, 496, 469-476.	13.7	961
75	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. <i>Immunity</i> , 2013, 38, 176-186.	6.6	374
76	Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. <i>Journal of Experimental Medicine</i> , 2011, 208, 2237-2249.	4.2	198
77	High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. <i>Journal of Virological Methods</i> , 2009, 158, 171-179.	1.0	235
78	Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. <i>Virology</i> , 2009, 394, 91-98.	1.1	28
79	Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia. <i>Journal of Virology</i> , 2008, 82, 12449-12463.	1.5	548
80	A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. <i>Virology</i> , 2006, 353, 268-282.	1.1	176
81	Immunogenicity of Constrained Monoclonal Antibody A32-Human Immunodeficiency Virus (HIV) Env gp120 Complexes Compared to That of Recombinant HIV Type 1 gp120 Envelope Glycoproteins. <i>Journal of Virology</i> , 2004, 78, 5270-5278.	1.5	40
82	HIV Vaccine Development at Duke University Medical Center. <i>Immunologic Research</i> , 2000, 22, 263-270.	1.3	0